bluebird bio provides update on 2seventy bio spin-off

bluebird bio has announced the filing by 2seventy bio of an updated Registration Statement with the US Securities and Exchange Commission (SEC).

This reflects bluebird bio’s plans for a spin-off of its oncology programmes and portfolio into 2seventy bio. The spin-off is on track to be completed by early November 2021.